Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma -: Results of a prospective Randomized trial of the German Low Grade Lymphoma Study Group (GLSG).

被引：0

作者：

Hiddemann, W

Dreyling, MH

Forstpointner, R

Kneba, M

Woermann, B

Lengfelder, E

Schmits, R

Reiser, M

Metzner, B

Schmitz, N

Truemper, L

Eimermacher, H

Parwaresch, R

机构：

[1] Univ Munich, Hosp Grosshadern, Dept Internal Med 3, D-80539 Munich, Germany

[2] Univ Hosp Schleswig Holstein, Dept Internal Med 2, Kiel, Germany

[3] Hosp Braunschweig, Dept Internal Med, Braunschweig, Germany

[4] Univ Heidelberg, Hosp Mannheim, Dept Internal Med 3, D-6900 Heidelberg, Germany

[5] Univ Hosp Homburg Saar, Dept Internal Med 1, Homburg, Germany

[6] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[7] Hosp Oldenburg, Dept Internal Med 2, Oldenburg, Germany

[8] Gen Hosp St Georg, Dept Internal Med, Hamburg, Germany

[9] Univ Hosp Goettingen, Dept Internal Med, Gottingen, Germany

[10] St Marien Hosp, Dept Med, Hagen, Germany

[11] Univ Hosp Schleswig Holstein, Dept Hematopathol, Kiel, Germany

来源：

BLOOD | 2003年 / 102卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

352

引用

页码：104A / 104A

页数：1

共 50 条

[1] Front - Line combined immuno-chemotherapy (R-CHOP) significantly improves the time to treatment failure and overall survival in elderly patients with advanced stage follicular lymphoma - Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG).
Buske, Christian
Kneba, Michael
Lengfelder, Eva
Pfreundschuh, Michael
Ludwig, Wolf-Dieter
Graeven, Ullrich
Hallek, Michael
Dreyling, Martin
Unterhalt, Michael
Hiddemann, Wolfgang
BLOOD, 2006, 108 (11) : 146A - 147A
[2] Combined immuno-chemotherapy (R-CHOP) results in significantly superior response rates and time to treatment failure in first line treatment of patients with lymphomplasmocytoid/ic immumocytoma (LP-IC) -: Results of a prospective randomized trial of the German Low grade Lymphoma Study Group (GLSG).
Buske, C
Dreyling, MH
Eimermacher, H
Boeck, HP
Pfreundschuh, M
Metzner, B
Fuchs, R
Woermann, B
Truemper, LH
Hess, G
Wandt, H
Ludwig, WD
Kreuser, ED
Schimke, J
Weh, HJ
Schmitz, S
Schmiegel, W
Unterhalt, M
Hiddemann, W
BLOOD, 2004, 104 (11) : 50A - 50A
[3] Combined immuno-chemotherapy (R-FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma -: Final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Dreyling, MH
Forstpointner, R
Repp, R
Hermann, S
Haenel, A
Metzner, B
Poll, C
Hartmann, F
Rothmann, F
Parwaresch, R
Unterhalt, M
Hiddemann, W
BLOOD, 2003, 102 (11) : 103A - 103A
[4] Evaluation of myeloablative therapy followed by autologous stem cell transplantation in first remission in patients with advanced stage follicular lymphoma after initial combined immuno-chemotherapy (R-CHOP) and conventional chemotherapy (CHOP): Analysis of 540 patients treated in prospective randomized trials of the German low grade lymphoma study group (GLSG)
Buske, C.
Dreyling, M. H.
Hoster, E.
Unterhalt, M.
Hiddemann, W.
ANNALS OF ONCOLOGY, 2008, 19 : 91 - 91
[5] The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)
C Buske
E Hoster
M Dreyling
H Eimermacher
H Wandt
B Metzner
R Fuchs
J Bittenbring
B Woermann
K Hohloch
G Hess
W-D Ludwig
J Schimke
S Schmitz
M Kneba
M Reiser
U Graeven
W Klapper
M Unterhalt
W Hiddemann
Leukemia, 2009, 23 : 153 - 161
[6] The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)
Buske, C.
Hoster, E.
Dreyling, M.
Eimermacher, H.
Wandt, H.
Metzner, B.
Fuchs, R.
Bittenbring, J.
Woermann, B.
Hohloch, K.
Hess, G.
Ludwig, W-D
Schimke, J.
Schmitz, S.
Kneba, M.
Reiser, M.
Graeven, U.
Klapper, W.
Unterhalt, M.
Hiddemann, W.
LEUKEMIA, 2009, 23 (01) : 153 - 161
[7] Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma: Follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Dreyling, MH
Forstpointner, R
Ludwig, WD
Gramatzki, M
Boeck, HP
Haenel, M
Wandt, H
Parwaresch, R
Unterhalt, M
Hiddemann, W
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 567S - 567S
[8] CHOP improves response rates but not overall survival in follicular and mantle cell lymphoma (MCL) -: Results of a randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
Nickenig, C
Dreyling, MH
Schiegnitz, E
Pfreundschuh, M
Truemper, LH
Reiser, M
Wandt, H
Lengfelder, E
Ludwig, WD
Berdel, WE
Metzner, B
Hess, G
Forstpointner, R
Parwaresch, R
Hasford, J
Unterhalt, M
Hiddemann, W
BLOOD, 2004, 104 (11) : 176A - 176A
[9] Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma:: Final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Dreyling, M.
Forstpointner, R.
Gramatzki, M.
Boeck, H.
Haenel, M.
Seymour, J.
Planker, M.
Duehrsen, U.
Wilms, K.
Unterhalt, M.
Hiddemann, W.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 422S - 422S
[10] Rituximab in combination with CHOP results in a significantly superior response rate and time to treatment failure in first-line treatment of lymphomplasmocytoid/ic immunocytoma (LP-IC) - A prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
Buske, C
Dreyling, M
Eimermacher, H
Boeck, H
Pfreundschuh, M
Metzner, B
Unterhalt, M
Hiddemann, W
ANNALS OF ONCOLOGY, 2005, 16 : 110 - 110

← 1 2 3 4 5 →